Improvement in health‐related quality of life and symptoms of anxiety and depression in patients with alopecia areata randomized to baricitinib or placebo: Results from two international randomized controlled trials

Abstract Background Alopecia areata (AA) is an autoimmune hair loss disorder associated with high rates of emotional and psychosocial distress. Baricitinib, an oral selective Janus kinase (JAK) 1 and JAK 2 inhibitor, was superior to placebo with respect to hair regrowth in two phase 3 trials involvi...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Bianca M. Piraccini, Manabu Ohyama, Brittany Craiglow, Anthony Bewley, Yuxin Ding, Yun‐Fei Chen, Yves Dutronc, Evangeline Pierce, Frederick Durand, Arash Mostaghimi
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Wiley 2024-03-01
Cyfres:	JEADV Clinical Practice
Pynciau:	alopecia areata baricitinib HADS and Skindex‐16 health‐related quality of life
Mynediad Ar-lein:	https://doi.org/10.1002/jvc2.269
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!